Applied Molecular Evolution Achieves Milestone in Chiron Collaboration.Business Editors and Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Dec. 17, 2002 Applied Molecular Evolution, Inc. (AME See AIT. ) (Nasdaq: AMEV AMEV Armored Medical Evacuation Vehicle ) today announced that it has achieved an initial milestone in its collaboration with Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. to optimize a non-antibody biotherapeutic candidate. Financial terms of the milestone were not disclosed. "The efficiency of the AMEsystem(TM), including the ExpressAME(TM) mammalian mammalian emanating from or pertaining to mammals. cell expression system, enabled us to reach this goal in nine months," stated William D. Huse, M.D., Ph.D., President, Chief Executive Officer and Chairman of AME. "AME has again demonstrated that our protein engineering technology has the control and precision to deliver improvements in the function of protein therapeutic candidates as specified by our collaborators, this time for Chiron, a leading developer of biotherapeutics." About Applied Molecular Evolution Applied Molecular Evolution, Inc., (AME) is a leader in applying directed molecular evolution to improve healthcare by optimizing and developing human biotherapeutics. Directed molecular evolution is a process for optimizing genes and proteins for specific commercial purposes. Since its inception, AME's principal focus has been on applying its proprietary AMEsystem(TM) technology platform to human biotherapeutics, the largest market for directed molecular evolution. Biotherapeutics, or biopharmaceuticals, are protein pharmaceuticals such as antibodies, cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , hormones and enzymes. AME uses its proprietary technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. For more information please visit www.AME.biz biz n. Informal Business. biz Noun Informal business Noun 1. . This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including uncertainties related to product development, uncertainties related to the need for regulatory or other government approvals, dependence on proprietary technology, uncertainty of market acceptance of the Company's products, uncertainties related to business opportunities, the receipt of future payments, including royalties, the continuation of customer relationships and other risks cited in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001, and other SEC Filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion